Date Time
Share
Case Western Reserve and Atelerix Life Sciences Inc. sign option license to develop new therapeutic approach to opioid crisis
Novel small molecule technology reverses life-threatening opioid-induced respiratory depression without diminishing pain relief
Case Western Reserve University and Atelerix Life Sciences Inc., a Charlottesville, Virginia-based biotechnology company, have signed a two-year option to license a novel family of small molecules called Active Thiol-Based Compounds (ATBC’s) to prevent or reverse life-threatening opioid-related side effects.
The lead compound, ATLX-0199 (also called sudaxine), will be first targeted at opioid-induced respiratory depression (OIRD) in the hospital setting.
A recent study by the medical technology company Medtronic found that 46% of surgical patients receiving opioids for post-operative pain-relief suffer one or more episodes of OIRD, presenting perhaps the most significant obstacle to discharge from intensive ca
CWRU, Atelerix sign option license to develop therapeutic approach to opioid crisis
CWRU, Atelerix sign option license to develop therapeutic approach to opioid crisis
Print
Case Western Reserve University and Atelerix Life Sciences Inc., a Charlottesville, Va.-based biotechnology company, have signed a two-year option to license novel, small-molecule technology to prevent or reverse life-threatening opioid-related side effects, according to a news release.
A recent study by medical technology company Medtronic found that 46% of surgical patients receiving opioids for post-operative pain relief suffer one or more episodes of opioid-induced respiratory depression (OIRD), presenting a significant obstacle to discharging patients from intensive care units and the hospital, the release stated.
E-Mail
IMAGE: Project leads for the team winning the top award are, from left, Arti Gaur, assistant professor of neurology at Geisel; Divya Ravi, Guarini 24, and Jordan Isaacs, Guarini 24, both. view more
Credit: (Photo by Kata Sasvari
Three teams of Dartmouth researchers have been selected to receive the first awards from the Dartmouth Innovations Accelerator for Cancer.
A philanthropy-funded initiative, the Accelerator was launched in 2020 by Norris Cotton Cancer Center and the Magnuson Center for Entrepreneurship to bring new cancer treatments to patients more quickly. So far, it has raised $3.3 million in philanthropic gifts and seeks to hit $5 million by June.
Philanthropy-Backed Accelerator Advances Cancer Therapies dartmouth.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dartmouth.edu Daily Mail and Mail on Sunday newspapers.
Related Company:
Three teams receive awards from the Dartmouth Innovations Accelerator for Cancer
Vermont Business Magazine Three teams of Dartmouth researchers have been selected to receive the first awards from the Dartmouth Innovations Accelerator for Cancer.
A philanthropy-funded initiative, the Accelerator was launched in 2020 by Norris Cotton Cancer Center and the Magnuson Center for Entrepreneurship to bring new cancer treatments to patients more quickly. So far, it has raised $3.3 million in philanthropic gifts and seeks to hit $5 million by June. When you look at the number of biotech start-ups that have spun out of our cancer center, it s astounding, says Steven Leach, director of Dartmouth s and Dartmouth-Hitchcock s Norris Cotton Cancer Center and the Preston T. and Virginia R. Kelsey Chair in Cancer at the Geisel School of Medicine. The Accelerator builds on our culture of collaboration and innovation. In its first year, it has attracted 17 teams, including